Vijay Pande discusses smaller bets and AI-native biotech investment strategy

Vijay Pande, formerly leading a16z's $4 billion biotech practice, has launched VZVC, a smaller AI-focused venture fund that takes a more selective investment approach. He believes biology is transitioning from a discovery-driven science to an engineering discipline, though clinical trials remain prohibitively expensive. Pande argues that open, shared datasets—rather than proprietary ones—are essential for AI to truly transform medicine.